Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy

Table 3

Relationship between pCR rates and molecular subtypes.

Molecular	pCR rates (%)	OR (95% CI)
HR+HER-2−	3.60	1 (ref)	—
HR+/HR−, HER-2+	9.60	2.82 (1.16–6.84)	0.02
TBC	14.30	4.40 (1.89–10.27)	0.001

TNBC: triple-negative breast cancer; HR: hormone receptor; HER-2 human epidermal growth factor receptor; TNBC: triple-negative breast cancer; pCR: pathological complete response; HR: hazard ratio; CI: confidence interval.